PAP
MAZE

Persistent Asset Partners’s Maze Therapeutics MAZE Stock Holding History

Persistent Asset Partners’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
8,768
+2,163
+33% +$95.5K 0.1% 165
2025
Q4 		$274K Buy
+6,605
New +$227K 0.12% 191

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Persistent Asset Partners's MAZE Position: Q1 2026 in Review

Persistent Asset Partners increased its Maze Therapeutics (MAZE) stake by 33% in Q1 2026, buying an estimated $95.5K and bringing the position to 8,768 shares worth $262K. The position accounts for 0.1% of the portfolio, ranked #165.

Persistent Asset Partners first reported a position in MAZE in Q4 2025 and has held it in 2 quarters since. The position peaked at $274K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Persistent Asset Partners held 8,768 shares of Maze Therapeutics worth $262K as of Q1 2026.
  • Persistent Asset Partners bought 2,163 Maze Therapeutics shares in Q1 2026, an estimated $95.5K.
  • Maze Therapeutics made up 0.1% of Persistent Asset Partners's portfolio in Q1 2026, its #165 holding.
  • Persistent Asset Partners first reported a position in Maze Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Maze Therapeutics position peaked at $274K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.